Simcere Pharmaceutical
Simcere Pharmaceutical Group, commonly known as Simcere, is a leading biopharmaceutical company headquartered in Nanjing, China. Founded in 1995, Simcere has established a strong presence in the pharmaceutical industry, focusing on the research, development, manufacturing, and marketing of innovative medicines. The company primarily operates in oncology, central nervous system disorders, and autoimmune diseases, with a commitment to enhancing patient outcomes through advanced therapeutics. With a robust portfolio of core products, including proprietary drugs and biosimilars, Simcere distinguishes itself through its dedication to quality and innovation. The company has achieved significant milestones, including successful collaborations and a growing international footprint, positioning itself as a key player in the global pharmaceutical market. Simcere's ongoing efforts in research and development underscore its commitment to addressing unmet medical needs and improving healthcare worldwide.
DitchCarbon Score
How does Simcere Pharmaceutical's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Medical Device Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Simcere Pharmaceutical's score of 15 is lower than 77% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Simcere Pharmaceutical's reported carbon emissions
In 2021, Simcere Pharmaceutical reported total carbon emissions of approximately 60,511,900 kg CO2e, a reduction from about 67,184,370 kg CO2e in 2020. The emissions breakdown for 2021 includes approximately 4,513,410 kg CO2e from Scope 1 and about 55,998,500 kg CO2e from Scope 2. This indicates a significant decrease in emissions, reflecting the company's efforts to improve its environmental performance. Despite these reductions, there are currently no disclosed targets for further emissions reductions or specific climate pledges. Simcere Pharmaceutical has not provided data on Scope 3 emissions, which encompass indirect emissions in the value chain. The company’s commitment to addressing climate change remains unclear, as no specific initiatives or targets have been outlined in their recent disclosures.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2020 | 2021 | |
|---|---|---|
| Scope 1 | 4,819,360 | 0,000,000 |
| Scope 2 | 62,365,010 | 00,000,000 |
| Scope 3 | - | - |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Simcere Pharmaceutical is not committed to any reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
